AbbVie (ABBV) Intangibles (2012 - 2026)

AbbVie (ABBV) reported Intangibles of $50.9 billion for Q1 2026, down 13.02% year-over-year from $58.5 billion in Q1 2025, and down 3.36% quarter-over-quarter from $52.6 billion in Q4 2025.

AbbVie (ABBV) Intangibles (2012 - 2026) Analysis & Trends

AbbVie (ABBV) has 15 years of Intangibles data on file, last reported at $50.9 billion in Q1 2026.

  • Intangibles for Q1 2026 came in at $50.9 billion, down 13.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.9 billion (down 13.02% YoY), and the FY2025 annual result was $52.6 billion, down 12.36% from the prior year.
  • Intangibles declined to $50.9 billion in Q1 2026 per ABBV's latest filing, from $52.6 billion in the prior quarter.
  • Over five years, Intangibles peaked at $74.0 billion in Q1 2022 and troughed at $711.0 million in Q3 2025.
  • A 5-year average of $58.4 billion and a median of $60.2 billion in 2024 frame the typical range for Intangibles.
  • The sharpest annual moves came in 2024 and 2025: Intangibles grew 13.72% in 2024, then plunged 98.93% in 2025.
  • A 5-year view of Intangibles shows it stood at $67.4 billion in 2022, then dropped by 17.54% to $55.6 billion in 2023, then grew by 8.02% to $60.1 billion in 2024, then slipped by 12.36% to $52.6 billion in 2025, then fell by 3.36% to $50.9 billion in 2026.
  • Business Quant data shows ABBV's Intangibles at $50.9 billion in Q1 2026, $52.6 billion in Q4 2025, and $711.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Intangibles (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 24.45 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 7.37 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn 49.06 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 50.87 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 25.75 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 21.38 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 16.38 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 52.56 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 18.24 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn - 10.60 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 50.87 Bn
Dec 31, 2025 52.64 Bn
Sep 30, 2025 711.00 Mn
Jun 30, 2025 57.03 Bn
Mar 31, 2025 58.49 Bn
Dec 31, 2024 60.07 Bn
Sep 30, 2024 66.65 Bn
Jun 30, 2024 60.24 Bn
Mar 31, 2024 62.23 Bn
Dec 31, 2023 55.61 Bn
Sep 30, 2023 58.60 Bn
Jun 30, 2023 62.86 Bn
Mar 31, 2023 64.85 Bn
Dec 31, 2022 67.44 Bn
Sep 30, 2022 68.73 Bn
Jun 30, 2022 71.82 Bn
Mar 31, 2022 73.99 Bn
Dec 31, 2021 75.95 Bn
Sep 30, 2021 77.46 Bn
Jun 30, 2021 79.34 Bn